Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 94.5% in March

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 115,900 shares, an increase of 94.5% from the February 28th total of 59,600 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average trading volume of 1,850,000 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Maxim Group started coverage on shares of Kazia Therapeutics in a research note on Thursday, February 6th. They issued a “buy” rating and a $3.00 target price for the company.

Kazia Therapeutics Trading Down 7.4 %

Shares of Kazia Therapeutics stock traded down $0.07 on Friday, reaching $0.88. 69,902 shares of the company were exchanged, compared to its average volume of 852,788. Kazia Therapeutics has a one year low of $0.76 and a one year high of $15.80. The company has a 50-day moving average of $1.09 and a 200 day moving average of $3.00.

Institutional Trading of Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Barclays PLC purchased a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned about 2.38% of Kazia Therapeutics at the end of the most recent quarter. 30.89% of the stock is owned by institutional investors and hedge funds.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.